Tirzepatide 40MG

Product details

Tirzepatide

CAS Number: 2023788-19-2
Molecular Formula: C225H348N48O68
Molecular Weight: ~4813.50 g/mol
INN (International Nonproprietary Name): Tirzepatide
Brand Name (for reference): Mounjaro® (Eli Lilly)
Sequence: Synthetic linear peptide composed of 39 amino acids, with C20 fatty diacid moiety for half-life extension
Form: White to off-white lyophilized powder
Purity: ≥98% (HPLC)
Solubility: Soluble in sterile water and aqueous buffers
Storage: −20°C (lyophilized); 2–8°C after reconstitution
Shelf Life: 24 months (lyophilized under recommended storage)

🔬 Product Overview:

Tirzepatide is a first-in-class dual GIP and GLP-1 receptor agonist, developed for the treatment of type 2 diabetes mellitus (T2DM) and obesity. It is a synthetic peptide analog that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor activity in a single molecule, offering synergistic glycemic control and weight loss effects.

Tirzepatide is studied and used in clinical settings for its significant metabolic benefits, including glycemic control, weight reduction, appetite suppression, and improvement in cardiometabolic risk factors.

✅ Key Features & Clinical Research Benefits:

Dual receptor agonism: GIP + GLP-1 for superior metabolic modulation

Improves insulin sensitivity and secretion

Reduces HbA1c and fasting/postprandial glucose levels

Promotes significant weight loss in obese and diabetic patients

Suppresses appetite and reduces food intake

Favorable safety profile, with lower risk of hypoglycemia

Cardiometabolic improvement: Reduces blood pressure, inflammation markers, and improves lipid profiles

⚙️ Mechanism of Action:

Tirzepatide mimics the actions of endogenous incretin hormones—GIP and GLP-1—by binding to and activating their respective receptors. Its dual agonist action leads to:

Enhanced glucose-dependent insulin secretion

Suppressed glucagon secretion

Slowed gastric emptying

Reduced appetite and caloric intake

Improved insulin sensitivity in peripheral tissues

The conjugation of a fatty acid moiety allows for once-weekly dosing by extending half-life via albumin binding and reduced renal clearance.